Compare TZOO & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | PYPD |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 73.0M |
| IPO Year | 2002 | 2020 |
| Metric | TZOO | PYPD |
|---|---|---|
| Price | $6.68 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $17.67 | $12.00 |
| AVG Volume (30 Days) | ★ 118.3K | 72.9K |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $89,923,000.00 | N/A |
| Revenue This Year | $11.57 | N/A |
| Revenue Next Year | $17.03 | N/A |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | ★ 6.58 | N/A |
| 52 Week Low | $6.59 | $2.30 |
| 52 Week High | $24.85 | $4.77 |
| Indicator | TZOO | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 78.14 |
| Support Level | $6.90 | $4.10 |
| Resistance Level | $7.30 | $4.63 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 3.59 | 78.02 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.